Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Mar

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Awareness of Alcohol-Cancer Link Holds Steady Despite Omission in New US Dietary Guidelines

Myelofibrosis Treatment Landscape Is Poised for Change

AI Model Classifies Challenging Thymic Epithelial Tumors

Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk

Lisocabtagene Maraleucel in Relapsed or Refractory MZL